Latest news with #Filament
Cision Canada
31-07-2025
- Health
- Cision Canada
FILAMENT HEALTH ANNOUNCES FIRST-EVER COMPASSIONATE USE APPROVAL FOR PSILOCYBIN IN THE EUROPEAN UNION
Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression VANCOUVER, BC, /CNW/ - Filament Health Corp. (OTC:FLHLF) (" Filament" or the " Company"), a clinical‐stage natural psychedelic drug development company, today announced the first-ever approval for compassionate use of psilocybin in the European Union (EU). The Company's botanical psilocybin drug candidate, PEX010, has been authorized for administration to a patient suffering from treatment-resistant depression (TRD) in Germany. The approval was granted under Germany's compassionate use framework and marks the first time psilocybin will be prescribed outside of a clinical trial in the EU. The treatment will be conducted by Dr. Gerhard Gründer at the Central Institute of Mental Health, Department of Molecular Neuroimaging. "This is a landmark moment for the field of psychedelic medicine in the European Union. Treatment-resistant depression affects up to 30% of individuals diagnosed with major depressive disorder and remains one of the most difficult psychiatric conditions to treat. Psilocybin has demonstrated significant promise as a novel therapeutic option, and this approval marks an important step toward expanding access for those in urgent need," said Dr. Gerhard Gründer. "I am honoured to play a role in expanding European access to psilocybin and grateful to the team at Filament Health for their support." "The approval of PEX010 for this milestone moment in European psilocybin access reinforces Filament's position as the world's leading supplier of GMP-quality psychedelic drug candidates," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "We're incredibly proud that our drug product will be the first psilocybin to be administered under compassionate use in the EU. It's a validation of Filament's ongoing efforts to make safe, standardized psychedelic medicines available to those who need them most." ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on X, Instagram, and LinkedIn. FORWARD LOOKING INFORMATION Certain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.
Daily Mirror
29-07-2025
- Entertainment
- Daily Mirror
How to throw the ultimate summer BBQ or picnic with kids at home - without breaking the bank
Entertaining guru Matilda Bea - who has more than 500,000 followers across Instagram and TikTok - shares her top 10 tips and reveals how to keep kids happy and parents sane all summer long With the school holidays in full swing and costs soaring, many families are skipping pricey outings and choosing to host garden BBQs and local park picnics instead. And according to entertaining expert Matilda Bea, that doesn't mean sacrificing fun or breaking the bank. According to a new survey, parents spend more than £100 extra per week over the summer holidays. But for those placing their children in clubs or camps, this rises to a staggering £385 per week, according to the Utility Warehouse survey that quizzed 1,000 parents of five to 15-year-old children. But having fun with the kids doesn't have to cost a fortune. Here, Matilda shares her top tips with the Mirror for summer BBQs and picnics that look and feel fabulous without breaking the bank. 1. Set the scene Matilda says lighting and tableware make all the difference. "String up fairy lights, use solar lanterns or pop candles in hurricane jars. The glow as the sun goes down transforms the space." Her favourite budget-friendly finds is the £20 Habitat Large Hurricane with Wooden Legs and the £15 Solar Filament Bulb Lantern to "create an instant good vibe". 2. Get inspired by TikTok BBQ season has gone viral once again on TikTok as Brits hope for another heatwave comeback this summer. "Whether you're taking full reign of the grill or curating the most epic spread of sides, it's all about teamwork, fun, and delicious food," Matilda says. "Sharing plates are a staple for making your BBQ or picnic look more curated - and it requires minimal effort." 3. Bring the indoors out Indoor/outdoor living can be a lifesaver for parents this summer, with bringing toys outside helping to keep the kids entertained while you are hosting. Layer up tablecloths, bring out proper cutlery and colourful dishes. "I hosted a garden party recently with 12 friends - tablecloths laid widthways and clashing napkins made it feel so joyful." Don't be afraid of colour. "Bold tones and mixed glassware add so much life to the table." 4. Pick a theme Not everything has to match, but a visual thread helps. "Lemons and blue for an Amalfi vibe, terracotta and wildflowers for Spanish summer." And for those wanting a money saving trick, Matilda suggests naming it "BYOB - bring your own buns!" 5. Plan for the British weather "Umbrellas, parasols, or even a chic throw-over pergola mean your party won't be a washout," she says. "And honestly, a little drizzle never hurt anyone when the spritzes are flowing and the playlists on point." 6. Create a Signature Station Matilda loves a station setup - drinks bars, condiments corners, even DIY sandwich or taco tables. And for the kids, these can be lifesavers if you set up a station just for them filled with their favourite snacks and drinks. "A drinks cart with elderflower spritzes or mocktails is such a moment. Or go full retro with a cordial and soda bar," she adds. "You can easily adapt this into a DIY ice cream bar, s'mores tray, or even a condiment corner with Sainsbury's Spicy Truffle Aioli - my favourite!" 7. Get ahead on prep 'Do what you can the night before - marinate skewers, chop salads, chill drinks. Then you're free to enjoy the day.' For shortcuts on a budget, Matilda swears by Sainsbury's summer range: 'The Coffee & Mascarpone Tart is a no-brainer for dessert.' 8. Seating is everything Low picnic rugs, poufs and fold-up chairs create a casual but stylish setup. "If you're heading to a local park, plenty of brands now offer beautiful foldable chairs and patterned rugs - they instantly elevate the setup and make it feel more curated." 9. Tableware Tableware doesn't have to cost a fortune and can be as simple as picking up some cheap, colourful tablecloths to throw over your old patio set. "A mix of vintage glasses or bold napkins can really bring the table to life," Matilda says. "Think clashing in the best way." 10. Tie it into summer sports With the Lionesses picking up a big win this weekend, it's the perfect time to plan ahead of more summer sports this season. "From F1 Sundays to the Euros or the Olympics, sport can be a great backdrop to your gathering," Matilda says. "Having it playing in the background gives everyone a natural talking point and keeps the energy upbeat, even during the mid-afternoon lull." Bonus tips for budget picnicking with the kids Freeze juice cartons for ice-cold drinks on the go Bring bubble wands or chalk for easy, mess-free park fun Use reusable plates and napkins to save money and waste Keep meals simple and sharable: pasta salads, wraps, cut fruit, and crisps always go down well Have kids help with the setup - it gives them a sense of pride and keeps them busy
Miami Herald
08-07-2025
- Business
- Miami Herald
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant - Erythroxylum coca and Erythroxylum novogranatense - from Peru has been signed between Peru's National Institute of Agrarian Innovation (INIA) and Psilo Scientific, a subsidiary of Filament Health Corp. (OTC:FLHLF) ("Filament"). The access agreement authorizes the research program of Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Filament, into a variety of potential mental health and central nervous system (CNS) indications for coca. "Psilo Scientific, Filament, Jaguar and Magdalena are very pleased about the signing of this coca access agreement," said Steven King, Ph.D., Jaguar's Chief Sustainable Supply and Ethnobotanical Research Officer and an Advisor to Magdalena. "As part of the authorization of this research project, an Internationally Recognized Certificate of Compliance (IRCC) has been granted and published on the Convention on Biological Diversity (CBD) website. The CBD is an international treaty for the conservation of biodiversity, the sustainable use of the components of biodiversity, and the equitable sharing of the benefits derived from the use of genetic resources. An IRCC is a key mechanism under the CBD and the Nagoya Protocol to ensure fair and equitable sharing of benefits from the use of genetic resources and indigenous knowledge." "The entire Magdalena team is deeply grateful to our Peruvian partner organizations in this research program, the Univeridad Nacional Agraria La Molina (La Molina) and the Empresa Nacional de La Coca (ENACO) for their collaboration, expertise and guidance," said Dr. King. "We are also grateful to the people of the Andean region who have domesticated the sacred plant, 'mama coca', which is and has been interwoven in the ritual, spiritual and traditional medicine of indigenous and non-indigenous communities for centuries. A great deal of the history and current work on coca was presented by indigenous leaders, scientists, government officials, social scientists and nonprofit public health experts in Peru at the Wisdom of the Leaf Coca Summit , organized by the McKenna Academy , in February 2025." Magdalena's mission is to develop novel, safe, efficacious next-generation psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health and CNS indications. "We believe that the development of Botanical Drugs from 'whole extract' coca leaf can provide therapeutic benefit, and that the development process will benefit the people of Peru, who have been sustainably producing coca leaves for several thousand years," said Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena. "In traditional medicine, coca leaves are utilized as a remedy for a wide variety of conditions, ranging from alleviating oral pain, digestive maladies, hunger, and altitude sickness, as well as muscular and skeletal aches. Many commonly used neuropsychiatric medications have side effects such as personality changes or sedation. With centuries of use by indigenous healers and traditional psychiatrists, plant-derived medicines offer potential new mechanisms of action for treating mental disorders while being potentially safer than chemically synthesized small molecule drugs that may have 'off target' effects." "The authorization from INIA to Magdalena and Psilo Scientific is a key step in the important work of exploring coca leaf's therapeutic potential for the treatment of various mental health and CNS indications," said Benjamin Lightburn, Chief Executive Officer of Filament Health and Magdalena Board Member. ABOUT MAGDALENA BIOSCIENCES Jaguar Health, Inc. and Filament Health Corp. formed Magdalena Biosciences, Inc. as a joint venture in 2023 to develop novel, natural prescription medicines derived from plants for mental health and CNS indications. Boulder, Colorado-based One Small Planet , founded by Will Peterffy, has committed to funding of US$1,000,000. The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders. ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates. Learn more at and on Twitter , Instagram and LinkedIn . ABOUT THE JAGUAR HEALTH FAMILY OF COMPANIES Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky , X , Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding the belief that the development of Botanical Drugs from 'whole extract' coca leaf can provide therapeutic benefit, and that the development process will benefit the people of Peru. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Source: Jaguar Health, Inc. Contact Info: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Malaysian Reserve
07-07-2025
- Health
- Malaysian Reserve
FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PSILOCYBIN FOR ALCOHOL USE DISORDER AND POST-TRAUMATIC STRESS DISORDER IN VETERANS AND FIRST RESPONDERS
The clinical trial at the University of Washington will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, July 7, 2025 /CNW/ – Filament Health Corp. (OTC:FLHLF) ('Filament' or the 'Company'), a clinical-stage natural psychedelic drug development company, today announced that the U.S. Food and Drug Administration (FDA) has authorized a phase 2 clinical trial studying the Company's botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) in military veterans and first responders. The trial will be led by Dr. Nathan Sackett at the University of Washington School of Medicine's Center for Novel Therapeutics in Addiction Psychiatry. It will be the first clinical trial to study the safety of psilocybin combined with psychological support for the treatment of individuals with both AUD and PTSD. 'Despite significant overlap between AUD and PTSD, there is a lack of evidence-based treatment options for people experiencing both conditions, particularly among veterans and first responders, who are disproportionately affected,' said Dr. Sackett, Principal Investigator and Assistant Professor in the Department of Psychiatry and Behavioral Sciences. 'This study will be the first to investigate the safety of psilocybin-assisted support in this dual-diagnosis population, and we are grateful to Filament for enabling this important research.' Military veterans and first responders experience some of the highest rates of co-occurring AUD and PTSD, yet treatment options remain limited and are often ineffective. While psychedelic-assisted therapies have shown promise for each condition individually, no prior trials have evaluated the use of psilocybin for both concurrently. This study will assess the safety of a single 25 mg dose of PEX010 paired with non-directive psychological support, defined by safety monitoring, empathetic presence, and integration sessions. 'Veterans and first responders dedicate their lives to protecting others, yet are often left behind with regard to mental health treatments,' said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. 'We're proud to contribute to this urgently needed research, which could help shape the future of care for those who have given so much to their communities.' The trial is funded by the State of Washington and is enrolling now, with results expected by fall 2026. Information regarding enrolment can be found at ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute 'forward–looking statements' and 'forward–looking information,' respectively, under Canadian securities legislation. Generally, forward–looking information can be identified by the use of forward–looking terminology such as, 'expect', 'anticipate', 'continue', 'estimate', 'may', 'will', 'should', 'believe', 'intends', 'forecast', 'plans', 'guidance' and similar expressions are intended to identify forward–looking statements or information. The forward–looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward–looking statements. Forward–looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward–looking statements or forward–looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward– looking statements and forward–looking information. Filament will not update any forward–looking statements or forward–looking information that are incorporated by reference herein, except as required by applicable securities laws.
Cision Canada
07-07-2025
- Health
- Cision Canada
FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PSILOCYBIN FOR ALCOHOL USE DISORDER AND POST-TRAUMATIC STRESS DISORDER IN VETERANS AND FIRST RESPONDERS
The clinical trial at the University of Washington will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, July 7, 2025 /CNW/ - Filament Health Corp. (OTC:FLHLF) (" Filament" or the " Company"), a clinical-stage natural psychedelic drug development company, today announced that the U.S. Food and Drug Administration (FDA) has authorized a phase 2 clinical trial studying the Company's botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) in military veterans and first responders. The trial will be led by Dr. Nathan Sackett at the University of Washington School of Medicine's Center for Novel Therapeutics in Addiction Psychiatry. It will be the first clinical trial to study the safety of psilocybin combined with psychological support for the treatment of individuals with both AUD and PTSD. "Despite significant overlap between AUD and PTSD, there is a lack of evidence-based treatment options for people experiencing both conditions, particularly among veterans and first responders, who are disproportionately affected," said Dr. Sackett, Principal Investigator and Assistant Professor in the Department of Psychiatry and Behavioral Sciences. "This study will be the first to investigate the safety of psilocybin-assisted support in this dual-diagnosis population, and we are grateful to Filament for enabling this important research." Military veterans and first responders experience some of the highest rates of co-occurring AUD and PTSD, yet treatment options remain limited and are often ineffective. While psychedelic-assisted therapies have shown promise for each condition individually, no prior trials have evaluated the use of psilocybin for both concurrently. This study will assess the safety of a single 25 mg dose of PEX010 paired with non-directive psychological support, defined by safety monitoring, empathetic presence, and integration sessions. "Veterans and first responders dedicate their lives to protecting others, yet are often left behind with regard to mental health treatments," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "We're proud to contribute to this urgently needed research, which could help shape the future of care for those who have given so much to their communities." The trial is funded by the State of Washington and is enrolling now, with results expected by fall 2026. Information regarding enrolment can be found at ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATION Certain statements and information contained in this press release and the documents referred to herein may constitute "forward–looking statements" and "forward–looking information," respectively, under Canadian securities legislation. Generally, forward–looking information can be identified by the use of forward–looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward–looking statements or information. The forward–looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward–looking statements. Forward–looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward–looking statements or forward–looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward– looking statements and forward–looking information. Filament will not update any forward–looking statements or forward–looking information that are incorporated by reference herein, except as required by applicable securities laws.
